摘要
目的探讨细胞周期调控因子E2F-3和pRb蛋白在前列腺癌发病机制中的作用及其临床意义。方法应用免疫组化E liV isionTMp lus二步法检测49例前列腺癌(prostate cancer,PCa)标本,20例良性前列腺增生(ben ign prostatichyperp lasia,BPH)及10例正常前列腺组织(norm al prostate,NP)中E2F-3与pRb蛋白的表达。结果E2F-3在PCa、BPH与NP中的阳性表达率为63.27%(31/49),20%(4/20)和10%(1/10),PCa中E2F-3的水平明显高于BPH(P<0.05)及NP(P<0.05),且与PCa病理分级临床分期呈正相关(rs分别为0.487、0.517,P<0.05)。pRb中在PCa,BPH与NP中的阳性表达率为44.90%(22/49),80%(16/20),90%(9/10),PCa中pRb的水平明显低于BPH及NP(P<0.05),且与PCa病理分级、临床分期呈负相关(rs分别为-0.401、-0.468,P<0.05)。E2F-3表达与pRb表达呈负相关(rs=-0.617,P<0.01)。结论E2F-3对PCa的发生发展发挥有重要的作用,且其表达与pRb蛋白的异常表达密切相关。
Objective To study the expression of E2F-3 and pRb in primary prostate cancer (PCa) and its clinical significance. Methods The expression of E2F-3 protein and pRb was detected in 49 PCa, 20 benign prostatic hyperplasia (BPH), 10 normal prostate tissues (NP) by EliVisionTM plus immunohistochemical staining. Results The positive expression rate of E2F-3 in PCa, BPH, NP was 63.27% (31/49), 20% (4/20) and 10% (1/10), respectively. The expression level of E2F-3 in PCa was significantly higher than that in BPH (P 〈 0.05 ) and NP ( P 〈 0.05 ), and was positively correlated with pathological grades ( r1 = 0. 487, P〈0.05) and clinical stages (r1 =0.517, P 〈0.05) of PCa. The positive expression rate of pRb in PCa, BPH, NP was 44.90% (22/49), 80% (16/20), 90% (9/10), respectively. The expression level of pRb in PCa was significantly lower than that in BPH ( P 〈 0.05 ) and NP ( P〈 0.05 ), and was negatively correlated with pathological grades ( r1 = - 0.401, P 〈0.05 ) and clinical stages ( r1 = - 0.468, P〈 0.05 ) of PCa. The expression level of E2F-3 in PCa was negatively correlated with pRb expression (r1 = -0.617, P 〈0.01 ). Conclusion E2F-3, closely associated with pRb, may play an important role in the genesis and progression of primary prostate cancer.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2006年第15期1611-1613,共3页
Journal of Third Military Medical University